An interventional study of WPPC and Whole egg powder in Post-menopausal Women and Post-menopausal Status, sponsored by University of Wisconsin, Madison. Recruiting at 1 site in United States. Open to female participants aged 51 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-29.
Sponsored by University of Wisconsin, Madison · Not applicable, Interventional, and Other
The goal of this clinical trial is to find out if dairy is a good source of choline compared to eggs. The main questions it aims to answer are:
Researchers will compare Whey Protein Phospholipid Concentrate (WPPC) to whole egg powder to see if WPPC is as effective as eggs.
Participants will drink a chocolate-flavored smoothie mixed with either WPPC or whole egg powder.
This study is intended to evaluate the bioavailability and metabolism of choline in WPPC compared to the most commonly -used food for bioavailable choline, whole egg. The intent of the evaluation is to improve the knowledge of how WPPC contributes to the nutritional needs and health of postmenopausal women.
Exclusion Criteria:
Participants will drink a chocolate-flavored smoothie with WPPC added
Dietary Supplement: WPPC
Participants will drink a chocolate-flavored smoothie with egg powder added
Dietary Supplement: Whole egg powder
A chocolate-flavored smoothie with WPPC added
A chocolate-flavored smoothie with whole egg powder added
Change in circulating choline
Circulating choline will be measured by UHPLC-HRMS/MS
Time frame: Baseline to 10 days
Change in co-factors in circulating choline
Co-factors in the circulation will be measured by ultrahigh performance liquid chromatography coupled with high resolution tandem mass spectrometry (UHPLC-HRMS/MS).
Time frame: Baseline to 10 days
Change in high-sensitivity C-reactive protein (hs-CRP)
Safety biomarker Hs-CRP will be measured using immunoturbidimetry.
Time frame: Baseline to 10 days
Change in circulating choline metabolites
Metabolites will be measured by UHPLC-HRMS/MS.
Time frame: Baseline to 10 days
Change in 8-hydroxydeoxyguanosine
The safety biomarker 8-hydroxydeoxyguanosine (8-OHDG) will be measured using enzyme-linked immunosorbent assay (ELISA).
Time frame: Baseline to 10 days
Change in aspartate transaminase
Aspartate transaminase (AST) will be measured using kinetic methods.
Time frame: Baseline to 10 days
Change in alanine transaminase (ALT)
Alanine transaminase will be measured using kinetic methods.
Time frame: Baseline to 10 days
Change in creatinine
Creatinine will be measured using kinetic methods
Time frame: Baseline to 10 days
Plan to share: Yes — The research team will share the individual participant data collected during the trial after deidentification. Deidentified data will be stored and shared with DryAd and in accordance with all applicable regulations.
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Wisconsin, Madison